4Mok CC,Tong KH,To CH,et al.Tacrolimus for induction therapy of diffuse proliferative lupus nephritis:an open-labeled pilot study.Kidney Int,2005,68(2):813 -817.
5Weening JJ,D'Agati VD,Schwartz MM,et al.The classification of glomerulonephritis in systemic lupus erythematosus revisited.Kidney Int,2004,65:521 -530.
6McCune WJ,Golbus J,Zeldes W,et al.Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus.N Engl J Med,1988,318 (22):1423-1431.
7Ong LM,Hooi LS,Lim TO,et al.Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.Nephrology (Carlton),2005,10 (5):504-510.
8Ginzler EM,Dooley MA,Aranow C,et al.Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.N Engl J Med,2005,353 (21):2219-2228.
9Sfikakis PP,Boletis JN,Lionaki S,et al.Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand:an open-label trial.Arthritis Rheum,2005,52 (2):501-513.
10Zhang X,Liu Z-h,Zheng J,et al.Influence of CY3A5 and MDR1polymorphisms on tacrolimus concertration in the early stage after renal transplantation.Clin Transplant,2005,19:638-643.
